William Mahlow, MD
Clinical Cardiac Electrophysiology · Knoxville, TNNPI 1205830171
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Medical Device Business Services, Inc. at 44.0% of the total. Reporting peaked in 2024 at $8,169 and has fallen 68.4% since, to $2,580 in 2025.
Across 345 payments — averaging $61.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$9K
- Boston Scientific$3K
- Abbott$2K
- Biosense Webster, Inc.$2K
- Medtronic$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- plus $3K from 31 others
What the payments were for
- Consulting fees$10,50049%
- Travel & lodging$4,46921%
- Food & beverage$6,35730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 9 | $9,375 |
| Boston Scientific | 56 | $2,937 |
| Abbott | 28 | $2,118 |
| Biosense Webster, Inc. | 12 | $1,536 |
| Medtronic | 15 | $1,352 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 64 | $1,260 |
| Novartis | 43 | $547 |
| Atricure, Inc. | 8 | $319 |
| Amgen | 20 | $308 |
| Pfizer | 16 | $245 |
| Johnson & Johnson | 14 | $196 |
| Boehringer Ingelheim | 8 | $126 |
| Sanofi-aventis U.S. LLC | 6 | $103 |
| E.r. Squibb & Sons, L.L.C. | 5 | $89 |
| Cardiva Medical, Inc. | 5 | $87 |
| Inspire Medical Systems, Inc. | 2 | $83 |
| Actelion Pharmaceuticals US, Inc. | 3 | $63 |
| Abiomed | 1 | $56 |
| Lundbeck LLC | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $44 |
| AstraZeneca | 3 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Impulse Dynamics (USA) Inc. | 1 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| Cook Medical LLC | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Gilead | 2 | $25 |
| Baxter Healthcare | 1 | $21 |
| Vital Connect, Inc | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Merck | 1 | $18 |
| Edwards Lifesciences | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Biotronik Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$10,610
- AVEIR$1,552
- EVERA MRI XT DR SURESCAN$922
- WATCHMAN FLX$131
How this compares
$21,325 in reported general payments places this provider in the 60th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.
See all clinical cardiac electrophysiology providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 116 | $100,678 |
| XareltoRivaroxaban | 69 | $62,696 |
| MultaqDronedarone Hcl | 11 | $16,169 |
| Repatha SureclickEvolocumab | 26 | $14,341 |
| Dofetilide | 18 | $3,584 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $3,204 |
| Ranolazine ErRanolazine | 12 | $2,050 |
| Flecainide Acetate | 31 | $1,299 |
| Potassium Chloride | 24 | $1,052 |
| Amiodarone Hcl | 45 | $842 |
| Atorvastatin Calcium | 60 | $482 |
| Metoprolol Succinate | 39 | $476 |
| Diltiazem 24hr ErDiltiazem Hcl | 13 | $460 |
| Rosuvastatin Calcium | 19 | $426 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 19 | $367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $245 | $100,678116 claims |
| Johnson & JohnsonXarelto | $196 | $62,69669 claims |
| Sanofi-aventis U.S. LLCMultaq | $103 | $16,16911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.
Other clinical cardiac electrophysiology in Knoxville
- Jeffrey HirshKnoxville$36K
- Michael BaileyKnoxville$27K
- Elliott GoodwinKnoxville$26K
- James CoxKnoxville$21K
- Nilamkumar PatelKnoxville$17K
- Thomas WannenburgKnoxville$8K
- William LindsayKnoxville$4K
- Hitesh MehtaKnoxville$4K
- Stephen FahrigNashville$605K
- Gregory BashianNashville$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.